The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia

COVID-19 Clinical Trial

Official title: The Impact of Hospital Care for COVID-19 on the Prevalence of Multidrug-resistant Microorganisms Among Patients Compared to Non-COVID-19 Hospital Care in Limited-resource Hospitals in Indonesia

Status Recruiting

Clinical Trial Summary

The effect of the COVID-19 pandemic on the emergence and spread of antibiotic-resistant bacteria is largely unknown, especially in low-resource settings. We aim to investigate the prevalence and relatedness of multidrug-resistant bacteria among patients in both COVID-19 and non-COVID-19 wards in two hospitals in Indonesia. Bacterial isolates will be collected from clinical sample and by screening of patients at discharge followed by 30 days after discharge. Aspects of hospital care that may be different in COVID-19 wards versus non-COVID-19 wards and that are considered important determinants for antimicrobial resistance (AMR) will be measured: hand hygiene compliance, use of personal protective equipment, and antibiotic use. Comparison of these data from COVID-19 wards to non-COVID-19 wards will increase our understanding of multidrug-resistant bacteria and provide further insight into the effect of interventions for AMR. The hypothesis of this study are: 1) the prevalence of multidrug-resistant bacteria in COVID-19 wards is higher than non-COVID-19 wards; 2) there is a relatedness of multidrug-resistant bacteria circulating either in the COVID-19 wards or non-COVID-19 wards; 3) the hand-hygiene compliance is lower in the COVID-19 wards than non-COVID-19 wards, however the personal protective equipment use compliance is higher in the COVID-19 wards than non-COVID-19 wards; 4) the antibiotic use in non-COVID-19 wards is better qualitatively; 5) the use of Ciprofloxacin, Gentamicin, and Ceftriaxone in non-COVID-19 wards is higher than in COVID-19 wards.

Clinical Trial Description

The overall objective of the study is to reveal the impact of hospital care for COVID-19 patients on the prevalence of MDRO among COVID-19 patients, compared to non-COVID-19 hospital care and the prevalence of MDRO among non-COVID-19 patients, with its underlying determinants in limited-resource hospitals in Indonesia. Specific aims of the study: 1. To measure the prevalence of MDRO in the COVID-19 wards compared to non-COVID-19 wards. 2. To investigate the transmission of the most prevalent MDRO in the COVID-19 wards compared to non-COVID-19 wards. 3. To analyze the hand hygiene compliance and use of PPE in COVID-19 wards compared to non-COVID-19 wards. 4. To analyze the antibiotic use in COVID-19 wards compared to non-COVID-19 wards. Design of the study: A prospective, observational cohort study will be performed in both COVID-19 wards and non-COVID-19 wards of a secondary care and a tertiary care hospital in the province of East Java in Indonesia. Both intensive care units (ICUs) and non-ICUs will be used. The tertiary care hospital in Malang is the Dr. Saiful Anwar hospital with 882 beds. Currently, 80 COVID-19 patients are admitted each month. The secondary care hospital has 250 beds, and approximately 25 COVID-19 patients are admitted each month. The specific aims will be addressed as follows: 1. MDRO prevalence The following MDROs will be included: MRSA, ESBL-producing Escherichia coli, ESBL-producing and carbapenemase-producing K. pneumoniae, carbapenem-resistant P. aeruginosa, and carbapenem-resistant A. baumannii. These will be searched for and collected via two approaches: 1. Detection by routine clinical cultures from patients during their hospital stay, both in the COVID-19 wards and non-COVID-19 wards. Blood, lower respiratory tract specimens, pus, and urine will be eligible for inclusion in the study. Identification and antibiotic susceptibility testing of the MDROs will be performed by the Vitek2 system. Demographic data and data on medical history, in-hospital mortality, length of stay, and antibiotic use will be collected from the medical records, according to the national regulations of medical research. The overall number of clinical cultures and their results will be collected for prevalence calculations (WHOnet). 2. As results from clinical cultures only reveal the tip of the MDRO iceberg, adult patients will be actively screened for MDRO carriage on the day of discharge and 30 days post-discharge from the COVID-19 ward and the non-COVID-19 ward, after informed consent. Discharge screening has been used as an approach in previous studies, and shown to be useful to detect MDRO transmission in the hospital. Screening on admission would be useful as well, but is not feasible on the COVID-wards due to workload when a patient is ill and needs immediate care. The 30-day post-discharge screening is a novel approach which may reveal MDROs that are still undetectable (i.e. in lowloads) in or on the patient's body on the moment of discharge, for example due to antibiotic use. All adult patients discharged from these wards are eligible for inclusion in the study. However, patients discharged within 48 hours of admission and patients who either live outside the city of Malang or their address is unclear are excluded. The 30-day post-discharge screening can be organized via the local public health centre. Sample size consideration: We expect to include at least 500 COVID-19 patients and 500 non-COVID-19 patients for MDRO detection from clinical culture, and at least 120 COVID-19 and 120 non-COVID-19 patients for active screening. Microbiological methods: Anterior nares and rectal swabs will be taken from each patient for discharge and post-discharge screening using sterile cotton swabs and transported to the laboratory in Amies transport medium for further processing within 24 hours of sampling. Isolation and identification of MDROs from the swabs will be performed as previously described. Confirmation of ESBL production will be done with the combination disk test, carbapenemase production with the CIM test. Isolates will be stored in duplicate as was done in our previous studies. 2. Analysis of MDRO transmission Detection of common resistance genes (i.e. mecA, blaNDM etc.) will be conducted by polymerase chain reaction. The clonality of MDROs will be evaluated for the most prevalent MDROs: by spa/MLVA typing (MRSA) and whole genome sequencing (Gram-negative MDRO; Illumina/nanopore). 3. Hand hygiene and PPE The direct observation method will be applied to establish hand hygiene compliance rate and use of PPE (gloves, gowns, masks). This will be done monthly during the one year period that bacterial isolates are collected. 4. Antibiotic use analysis Qualitative evaluation of antibiotic use will be performed by the Gyssens' algorithm and subsequent comparison of COVID-19 patients and non-COVID-19 patients either with or without MDRO infection or colonization. Furthermore, the DDD value of ceftriaxone, gentamicin, and ciprofloxacin will be compared. ;

Related Conditions & MeSH terms

• Antibiotic Resistant Infection
• COVID-19

• NCT number: NCT05293483
• Study type: Observational [Patient Registry]
• Source: Erasmus Medical Center
• Contact: Dewi Santosaningsih, PhD
• Phone: +62-341-569117
• Email: dewi.santosa@ub.ac.id
• Status: Recruiting
• Start date: March 7, 2022
• Completion date: March 7, 2023